Loading clinical trials...

Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma

Phase 2 Study of Canfosfamide HCl for Injection (Telcyta®, TLK286)in Refractory or Relapsed Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma (DLBCL) and Multiple Myeloma (MM)

NCT01148108•Telik

View on ClinicalTrials.gov

Summary

This is a Phase 2 study to determine the efficacy and safety of canfosfamide treatment in relapsed or refractory mantle cell lymphoma, diffuse large B cell lymphoma and multiple myeloma. The study will be conducted in two stages with 5-6 patients in each indication in Stage 1 and if responses are observed an additional 10 patients in Stage 2 in each group.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•relapsed or refractory disease
•histologically or cytologically confirmed disease
•characteristic immunophenotypic profiles
•measurable disease (for lymphoma patients)
•ECOG performance status of 0-2
•adequate liver and kidney function
•adequate bone marrow reserves
•ineligible or unwilling to undergo autologous stem cell transplantation

Exclusion Criteria

•failure to recover from any major surgery within 4 weeks of study entry
•pregnant or lactating women
•women of child-bearing potential not using reliable and appropriate contraception
•routine prophylactic use of G-CSF required within 2 weeks of study entry
•Grade 3 or higher peripheral neuropathy
•history of hepatitis B virus or HIV
•central nervous system or meningeal involvement by lymphoma or multiple myeloma

Locations (1)

Cancer Institute of New Jersey

New Brunswick, New Jersey, United States

Key Dates

Start Date

June 1, 2010

Primary Completion Date

September 1, 2012

Completion Date

September 1, 2012

Last Updated

March 15, 2013

Enrollment

ACTUAL participants

Conditions

Mantle Cell LymphomaB Cell LymphomaMultiple Myeloma

Interventions

Canfosfamide HCl for injection

DRUG

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

NCT05529069

Mantle Cell LymphomaNon Hodgkin Lymphoma+1 more

View study

RECRUITINGPHASE2

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

NCT06179888

Multiple Myeloma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 15, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma

Inclusion Criteria

Exclusion Criteria

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies